BELGRADE, SERBIA, July 28 /PRNewswire-FirstCall/ - Hard to Treat Diseases, Inc. (HTDS:PK) http://www.htdsmedical.com, Slavica Bio Chem Division (Slavica) intends to re release a TV feature on the work of the medical team in the area of potential treatment of MS. The TV feature was aired in Europe only, several years ago.
Dr. Sanja Pekovic, Chief Project Scientist, Chief Strategy Officer explains: "A few years ago Serbian government TV did a feature about our work, and it took a great public attention. It was about Multiple sclerosis, current therapies, there were also some patients, and our whole team. All of us were talking about our work, our results, our lab was also presented. Also, there were some short movies about MS. It was very good and they repeated it several times on TV." Currently the company is in the process of obtaining translations and writing to the Director of RTS (TV) and intends to post the interview on its corporate web sites www.slavicabiotech.com and www.htdsmedical.com. The company intends to make use of other media ie CD/DVD and similar to distribute the content to other medical professionals, research organizations, and companies in the medical industry to shed additional spotlight on the work of the Slavica Bio Tech team.
In other company news, within the next few weeks Slavica Bio Tech division intends to conduct a web cast only to address the work of Slavica. Dr.Sanja Pekovic, added: "Considering the potential, the exposure, and the spotlight this interview may bring to the company we are grateful and it is our pleasure, to have Professor Rakic (See Biography Link) (http://www.sanu.ac.rs/English/Clanstvo/Biografije/LjubisavRakic.pdf ) accept our invitation to be Slavica's spokesperson for the web cast. He is our Chief scientist and Ribavirin was his idea at the start. Professor Rakic is a well known and highly regarded and respected scientist. He is also the Vice-President of the Serbian Academy of Sciences and Arts in charge for natural sciences."
Company followers are advised that a similar and a second web cast is being planned to feature only the Mellow Hope (HTDS China Subsidiary Vaccine Division) http://www.mellowhope.com/en/main.asp. This second webcast will be chaired by the HTDS CEO, Mr. Terry Yuan.
Dr Pekovic concluded: "We are eager to get the message out to the industry on the work that our team is doing at Slavica. By that we mean not only to our shareholders but to the medical industry as well. We believe that our work is invaluable, that we have made some significant strides, which simply cannot be ignored and we believe that the market is just starting to take notice of our potential. To that end we have hired a liaison contact person, Dr. Ivana Gadjanski. Ivana comes highly qualified to us. She is a PhD. She has recently returned from Germany where she finished her PhD studies and got her PhD diploma, and now is a part of our team. Also, she is an assistant professor at the State University Novi Pazar, she speaks: English -professionally, CAE certificate, grades A, German - upper intermediate level, French - basics and is an enthusiastic young scientist with a lot of fresh and original ideas.
In our team she is responsible for introducing stem cell therapy in our models of EAE/MS and traumatic brain injury. Her duties will also include sending regular updates of our work to our North American office, the head office in China, and having our North American office and our advisors disseminate timely updates to the HTDS followers, shareholders and the medical professionals."
The company intends to provide many updates on the work and HTDS activities on a timely basis.
Safe Harbor Statement
Information in this filing may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases, Inc. that constitute forward-looking statements for purposes of the safe harbor Provision's under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project," and similar words and phrases are intended to identify such forward-looking statements. HTDS Corporation cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases, Inc. is not a guarantee of future performance. None of the information in this filing constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases, Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases, Inc.'s control. In addition to those discussed in Hard to Treat Diseases, Inc.'s press releases, public filings, and statements by Hard to Treat Diseases, Inc.'s management, including, but not limited to, Hard to Treat Diseases, Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases, Inc.'s ability to raise additional capital to fund future operations, HTDS Corporation's ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Hard to Treat Diseases, Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases, Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.
|SOURCE Hard to Treat Diseases|
Copyright©2009 PR Newswire.
All rights reserved